Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
China Great Wall Asset Management is a major Chinese state-owned enterprise specializing in the acquisition and disposal of distressed assets—primarily non-performing loans from banks. It was established in 1999 as one of four national asset management companies to address bad debts following the Asian financial crisis. The company does not operate in life sciences, biotech, pharma, or healthcare sectors[1][3].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on China Great Wall Asset Management.